Hyunjin Heo

  • Citations Per Year
Learn More
BACKGROUND Evaluating the potential risk of metabolic drug-drug interactions (DDIs) is clinically important. OBJECTIVE To develop a physiologically based pharmacokinetic (PBPK) model for sarpogrelate hydrochloride and its active metabolite, (R,S)-1-{2-[2-(3-methoxyphenyl)ethyl]-phenoxy}-3-(dimethylamino)-2-propanol (M-1), in order to predict DDIs between(More)
  • 1